Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

81. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Full Text available with Trip Pro

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Kansal AR, Sharma M (...) , Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of dabigatran versus rivaroxaban as anticoagulation therapies for prevention

2012 NHS Economic Evaluation Database.

82. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Full Text available with Trip Pro

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism (...) with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P=0.003) for the primary efficacy outcome

2012 NEJM Controlled trial quality: predicted high

83. Rivaroxaban in patients with a recent acute coronary syndrome. Full Text available with Trip Pro

Rivaroxaban in patients with a recent acute coronary syndrome. Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recent acute coronary syndrome to receive twice-daily doses (...) of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to 31 months. The primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke.Rivaroxaban significantly reduced the primary efficacy end point, as compared with placebo, with respective rates of 8.9% and 10.7% (hazard ratio in the rivaroxaban group, 0.84; 95% confidence interval [CI], 0.74 to 0.96; P=0.008), with significant improvement for both the twice-daily 2.5-mg

2012 NEJM Controlled trial quality: predicted high

84. What role can dabigatran,rivaroxaban and apixaban play in the future?

What role can dabigatran,rivaroxaban and apixaban play in the future? Vol 19. DTB: Vol 19, No 3. May - July 2011 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 19, No 3. May - July 2011 DTB: Vol 19, No 3. May - July 2011 Content tools Share it What role can dabigatran, rivaroxaban and apixaban play in the future? Dabigatran, rivaroxaban and apixaban have shown to be non inferior to warfarin. However these drugs might

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

85. Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations. (Abstract)

Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations. 21992495 2011 11 23 2015 11 19 1533-4406 365 17 2011 Oct 27 The New England journal of medicine N. Engl. J. Med. Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. 1557-9 10.1056/NEJMp1110639 Fleming Thomas R TR Department of Biostatistics, University of Washington, Seattle, USA. Emerson Scott S SS eng Journal Article 2011 10 05 United States N Engl J Med 0255562 0028-4793 (...) 0 Anticoagulants 0 Morpholines 0 Thiophenes 9NDF7JZ4M3 Rivaroxaban AIM IM Advisory Committees Anticoagulants therapeutic use Atrial Fibrillation drug therapy Clinical Trials as Topic Drug Approval legislation & jurisprudence Government Regulation Humans Morpholines therapeutic use Rivaroxaban Thiophenes therapeutic use United States United States Food and Drug Administration 2011 10 14 6 0 2011 10 14 6 0 2011 12 13 0 0 ppublish 21992495 10.1056/NEJMp1110639

2011 NEJM

86. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery (...) Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. Oslo: Norwegian Knowledge Centre

2011 Health Technology Assessment (HTA) Database.

87. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison

Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

88. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]

[Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L (...) . Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No 41. 2011 Authors' objectives To assess the available evidence on the efficacy, safety and other issues related with coverage policies on the use of dabigatran and rivaroxaban as thrombophylaxis after a major orthopedic surgery. Authors

2011 Health Technology Assessment (HTA) Database.

89. Xarelto (rivaroxaban)

Xarelto (rivaroxaban) Drug Approval Package: Xarelto (rivaroxaban) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Xarelto (rivaroxaban) 10 mg immediate release Tablets Company: Johnson and Johnson Pharmaceutical Research and Development, LLC Application No.: 022406 Approval Date: 07/01/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

90. Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Drug Approval Package: Xarelto (Rivaroxaban) NDA 202439 U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Xarelto (Rivaroxaban) NDA 202439 Company: Janssen Pharmaceuticals Application No.: 202439 Approval Date: 11/04/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

91. Randomised controlled trial: Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications

Randomised controlled trial: Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications Article Text Therapeutics Randomised controlled trial Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications David J Rosenberg 1 , Jack Ansell 2 Statistics from

2011 Evidence-Based Medicine

92. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Full Text available with Trip Pro

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong (...) L, Lees M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after surgery in patients undergoing total hip or knee

2011 NHS Economic Evaluation Database.

93. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Full Text available with Trip Pro

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (...) (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism.In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P<0.001 for noninferiority

2011 NEJM Controlled trial quality: predicted high

94. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

95. Oral rivaroxaban for symptomatic venous thromboembolism. Full Text available with Trip Pro

Oral rivaroxaban for symptomatic venous thromboembolism. Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (...) (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding

2010 NEJM Controlled trial quality: predicted high

96. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement Full Text available with Trip Pro

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement A once-daily dose of rivaroxaban 10 mg, an oral, direct Factor Xa inhibitor, was compared with enoxaparin 40 mg subcutaneously once daily for prevention of venous thromboembolism in three studies of patients undergoing elective hip and knee replacement (RECORD programme). A pooled analysis of data from these studies (n = 9581) showed that rivaroxaban was more effective than (...) %). Rivaroxaban started six to eight hours after surgery was more effective than enoxaparin started the previous evening in preventing symptomatic venous thromboembolism and all-cause mortality, without increasing major bleeding.

2009 EvidenceUpdates Controlled trial quality: uncertain

97. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170) Overview | Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | Guidance | NICE Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Technology appraisal guidance [TA170] Published date: 22 April 2009 Share Guidance on rivaroxaban (Xarelto) for preventing venous

2009 National Institute for Health and Clinical Excellence - Technology Appraisals

98. Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement

Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement Home - Monash Health Find a Location Latest news Victorian Minister for Health Jenny Mikakos MP meets a patient and researcher leading the world-first safety trial examining stem cells as therapy for acute stroke. Your health Heat kills more people than any natural disaster. Be prepared and survive the heat this summer. Our children’s hospital Monash Children’s Hospital is one of Australia’s

2009 Monash Health Evidence Reviews

99. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 170. 2009 Authors' conclusions Rivaroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip

2009 Health Technology Assessment (HTA) Database.

100. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

2009 Health Technology Assessment (HTA) Database.